Engineered Extracellular Vesicles for Targeted Reprogramming of Cancer-associated Fibroblasts to Potentiate Therapy of Pancreatic Cancer

Overview

Journal Signal Transduct Target Ther

Specialties Cell Biology
Pharmacology

Date 2024 Jun 23

PMID 38910148

Authors

Pengcheng Zhou

Xuanlong Du

Weilu Jia

Kun Feng

Yewei Zhang

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is one of the deadly malignancies with a significant mortality rate and there are currently few therapeutic options for it. The tumor microenvironment (TME) in pancreatic cancer, distinguished by fibrosis and the existence of cancer-associated fibroblasts (CAFs), exerts a pivotal influence on both tumor advancement and resistance to therapy. Recent advancements in the field of engineered extracellular vesicles (EVs) offer novel avenues for targeted therapy in pancreatic cancer. This study aimed to develop engineered EVs for the targeted reprogramming of CAFs and modulating the TME in pancreatic cancer. EVs obtained from bone marrow mesenchymal stem cells (BMSCs) were loaded with miR-138-5p and the anti-fibrotic agent pirfenidone (PFD) and subjected to surface modification with integrin α5-targeting peptides (named IEVs-PFD/138) to reprogram CAFs and suppress their pro-tumorigenic effects. Integrin α5-targeting peptide modification enhanced the CAF-targeting ability of EVs. miR-138-5p directly inhibited the formation of the FERMT2-TGFBR1 complex, inhibiting TGF-β signaling pathway activation. In addition, miR-138-5p inhibited proline-mediated collagen synthesis by directly targeting the FERMT2-PYCR1 complex. The combination of miR-138-5p and PFD in EVs synergistically promoted CAF reprogramming and suppressed the pro-cancer effects of CAFs. Preclinical experiments using the orthotopic stroma-rich and patient-derived xenograft mouse models yielded promising results. In particular, IEVs-PFD/138 effectively reprogrammed CAFs and remodeled TME, which resulted in decreased tumor pressure, enhanced gemcitabine perfusion, tumor hypoxia amelioration, and greater sensitivity of cancer cells to chemotherapy. Thus, the strategy developed in this study can improve chemotherapy outcomes. Utilizing IEVs-PFD/138 as a targeted therapeutic agent to modulate CAFs and the TME represents a promising therapeutic approach for pancreatic cancer.

Citing Articles

Exosomes derived from FN14-overexpressing BMSCs activate the NF-κB signaling pathway to induce PANoptosis in osteosarcoma.

Wang L, Huang Y, Zhang X, Chen W, Dai Z Apoptosis. 2025; .

PMID: 39833632 DOI: 10.1007/s10495-024-02071-z.

A Novel Oncolytic Virus Formulation Based on Mesenchymal Stem Cell-Derived Vesicles for Tumor Therapy.

Zeng F, Huang Y, Xu B, Yao L, Zhang Y, Gao Z J Cancer. 2025; 16(3):700-707.

PMID: 39781350 PMC: 11705066. DOI: 10.7150/jca.104066.

Targeted delivery of extracellular vesicles: the mechanisms, techniques and therapeutic applications.

Zhao S, Di Y, Fan H, Xu C, Li H, Wang Y Mol Biomed. 2024; 5(1):60.

PMID: 39567444 PMC: 11579273. DOI: 10.1186/s43556-024-00230-x.

Decoding tumor-fibrosis interplay: mechanisms, impact on progression, and innovative therapeutic strategies.

Chen H, Xu X, Li J, Xue Y, Li X, Zhang K Front Pharmacol. 2024; 15:1491400.

PMID: 39534084 PMC: 11555290. DOI: 10.3389/fphar.2024.1491400.

References

Li X, Li Y, Yu C, Bao H, Cheng S, Huang J . ROS-Responsive Janus Au/Mesoporous Silica Core/Shell Nanoparticles for Drug Delivery and Long-Term CT Imaging Tracking of MSCs in Pulmonary Fibrosis Treatment. ACS Nano. 2023; 17(7):6387-6399. DOI: 10.1021/acsnano.2c11112. View

Zhao S, Guan B, Mi Y, Shi D, Wei P, Gu Y . LncRNA MIR17HG promotes colorectal cancer liver metastasis by mediating a glycolysis-associated positive feedback circuit. Oncogene. 2021; 40(28):4709-4724. PMC: 8282501. DOI: 10.1038/s41388-021-01859-6. View

Wang Y, Pei Y, Sun Y, Zhou S, Zhang X, Pei M . Stem cells immortalized by hTERT perform differently from those immortalized by SV40LT in proliferation, differentiation, and reconstruction of matrix microenvironment. Acta Biomater. 2021; 136:184-198. PMC: 8627502. DOI: 10.1016/j.actbio.2021.09.021. View

Wang Y, Li C, Zhao R, Qiu Z, Shen C, Wang Z . CircUbe3a from M2 macrophage-derived small extracellular vesicles mediates myocardial fibrosis after acute myocardial infarction. Theranostics. 2021; 11(13):6315-6333. PMC: 8120198. DOI: 10.7150/thno.52843. View

Kalluri R, McAndrews K . The role of extracellular vesicles in cancer. Cell. 2023; 186(8):1610-1626. PMC: 10484374. DOI: 10.1016/j.cell.2023.03.010. View

Selvaggio A, Noble P . Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis. Annu Rev Med. 2015; 67:487-95. DOI: 10.1146/annurev-med-120214-013614. View

Zhang P, Wang J, Luo W, Yuan J, Cui C, Guo L . Kindlin-2 Acts as a Key Mediator of Lung Fibroblast Activation and Pulmonary Fibrosis Progression. Am J Respir Cell Mol Biol. 2021; 65(1):54-69. DOI: 10.1165/rcmb.2020-0320OC. View

Wu Q, Gui W, Jiao B, Han L, Wang F . miR-138 inhibits epithelial-mesenchymal transition in silica-induced pulmonary fibrosis by regulating ZEB2. Toxicology. 2021; 461:152925. DOI: 10.1016/j.tox.2021.152925. View

Hosein A, Brekken R, Maitra A . Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020; 17(8):487-505. PMC: 8284850. DOI: 10.1038/s41575-020-0300-1. View

10.

Mediavilla-Varela M, Boateng K, Noyes D, Antonia S . The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. BMC Cancer. 2016; 16:176. PMC: 4776434. DOI: 10.1186/s12885-016-2162-z. View

11.

Sahai E, Astsaturov I, Cukierman E, DeNardo D, Egeblad M, Evans R . A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020; 20(3):174-186. PMC: 7046529. DOI: 10.1038/s41568-019-0238-1. View

12.

Zhao W, Zhang R, Zang C, Zhang L, Zhao R, Li Q . Exosome Derived from Mesenchymal Stem Cells Alleviates Pathological Scars by Inhibiting the Proliferation, Migration and Protein Expression of Fibroblasts via Delivering miR-138-5p to Target SIRT1. Int J Nanomedicine. 2022; 17:4023-4038. PMC: 9467851. DOI: 10.2147/IJN.S377317. View

13.

Desi N, Teh V, Tong Q, Lim C, Tabatabaeian H, Chew X . MiR-138 is a potent regulator of the heterogenous MYC transcript population in cancers. Oncogene. 2021; 41(8):1178-1189. PMC: 8856960. DOI: 10.1038/s41388-021-02084-x. View

14.

Zhu Z, Zhai Y, Hao Y, Wang Q, Han F, Zheng W . Specific anti-glioma targeted-delivery strategy of engineered small extracellular vesicles dual-functionalised by Angiopep-2 and TAT peptides. J Extracell Vesicles. 2022; 11(8):e12255. PMC: 9451528. DOI: 10.1002/jev2.12255. View

15.

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

16.

Zhan J, Song J, Wang P, Chi X, Wang Y, Guo Y . Kindlin-2 induced by TGF-β signaling promotes pancreatic ductal adenocarcinoma progression through downregulation of transcriptional factor HOXB9. Cancer Lett. 2015; 361(1):75-85. DOI: 10.1016/j.canlet.2015.02.039. View

17.

Kang J, Yang M, Kwan Kwon T, Kim D, Park C . Inhaled deep eutectic solvent based-nanoemulsion of pirfenidone in idiopathic pulmonary fibrosis. J Control Release. 2022; 352:570-585. DOI: 10.1016/j.jconrel.2022.10.045. View

18.

Li D, She J, Hu X, Zhang M, Sun R, Qin S . The ELF3-regulated lncRNA UBE2CP3 is over-stabilized by RNA-RNA interactions and drives gastric cancer metastasis via miR-138-5p/ITGA2 axis. Oncogene. 2021; 40(35):5403-5415. PMC: 8413130. DOI: 10.1038/s41388-021-01948-6. View

19.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

20.

Bian S, Dong H, Zhao L, Li Z, Chen J, Zhu X . Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer. Adv Sci (Weinh). 2022; 9(29):e2201931. PMC: 9561769. DOI: 10.1002/advs.202201931. View